These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2106402)

  • 21. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
    Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An evaluation of the DDAVP infusion test with PFA-100 and vWF activity assays to distinguish vWD types in children.
    Akin M; Karapinar DY; Balkan C; Ay Y; Kavakli K
    Clin Appl Thromb Hemost; 2011 Oct; 17(5):441-8. PubMed ID: 20460340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A trial of desmopressin to reduce blood loss in patients undergoing spinal fusion for idiopathic scoliosis.
    Guay J; Reinberg C; Poitras B; David M; Mathews S; Lortie L; Rivard GE
    Anesth Analg; 1992 Sep; 75(3):405-10. PubMed ID: 1510262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Shortening of bleeding time by 1-deamino-8-arginine vasopressin (DDAVP) in the absence of platelet von Willebrand factor in Gray platelet syndrome.
    Pfueller SL; Howard MA; White JG; Menon C; Berry EW
    Thromb Haemost; 1987 Dec; 58(4):1060-3. PubMed ID: 3502198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. von Willebrand factor interaction with the glycoprotein IIb/IIa complex. Its role in platelet function as demonstrated in patients with congenital afibrinogenemia.
    De Marco L; Girolami A; Zimmerman TS; Ruggeri ZM
    J Clin Invest; 1986 Apr; 77(4):1272-7. PubMed ID: 3007578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does desmopressin acetate reduce blood loss after surgery in patients on cardiopulmonary bypass?
    Rocha E; Llorens R; Páramo JA; Arcas R; Cuesta B; Trenor AM
    Circulation; 1988 Jun; 77(6):1319-23. PubMed ID: 3286039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Desmopressin treatment improves platelet function under flow in patients with postoperative bleeding.
    Swieringa F; Lancé MD; Fuchs B; Feijge MA; Solecka BA; Verheijen LP; Hughes KR; van Oerle R; Deckmyn H; Kannicht C; Heemskerk JW; van der Meijden PE
    J Thromb Haemost; 2015 Aug; 13(8):1503-13. PubMed ID: 25988848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adventures in hemostasis. Desmopressin in cardiac surgery.
    Salzman EW; Weinstein MJ; Reilly D; Ware JA
    Arch Surg; 1993 Feb; 128(2):212-7. PubMed ID: 8431122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
    van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
    Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response of patients with hemophilia A and von Willebrand disease to desmopressin (DDAVP).
    Santiago-Borrero PJ; Casanova R
    Bol Asoc Med P R; 1990 May; 82(5):207-10. PubMed ID: 2115785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers.
    Casonato A; Pontara E; Dannhäuser D; Bertomoro A; Sartori MT; Girolami A
    Haematologia (Budap); 1994; 26(2):97-109. PubMed ID: 7890268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of desmopressin acetate (DDAVP) on postoperative blood loss after cardiac operations in children.
    Seear MD; Wadsworth LD; Rogers PC; Sheps S; Ashmore PG
    J Thorac Cardiovasc Surg; 1989 Aug; 98(2):217-9. PubMed ID: 2666759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van Vliet HH
    Acta Haematol; 2009; 121(2-3):85-97. PubMed ID: 19506353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biologic response to subcutaneous and intranasal therapy with desmopressin in a large Amish kindred with Type 2M von Willebrand disease.
    Sharthkumar A; Greist A; Di Paola J; Winay J; Roberson C; Heiman M; Herbert S; Parameswaran R; Shapiro A
    Haemophilia; 2008 May; 14(3):539-48. PubMed ID: 18312368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
    Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine.
    Cattaneo M; Lombardi R; Bettega D; Lecchi A; Mannucci PM
    Arterioscler Thromb; 1993 Mar; 13(3):393-7. PubMed ID: 8443143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.